全文获取类型
收费全文 | 355篇 |
免费 | 2篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 91篇 |
妇产科学 | 20篇 |
基础医学 | 18篇 |
口腔科学 | 7篇 |
临床医学 | 13篇 |
内科学 | 41篇 |
皮肤病学 | 16篇 |
神经病学 | 7篇 |
外科学 | 62篇 |
综合类 | 2篇 |
预防医学 | 32篇 |
眼科学 | 4篇 |
药学 | 29篇 |
肿瘤学 | 9篇 |
出版年
2022年 | 1篇 |
2021年 | 3篇 |
2017年 | 2篇 |
2016年 | 1篇 |
2013年 | 2篇 |
2012年 | 2篇 |
2011年 | 1篇 |
2010年 | 6篇 |
2009年 | 3篇 |
2008年 | 1篇 |
2007年 | 2篇 |
2006年 | 1篇 |
2000年 | 4篇 |
1999年 | 3篇 |
1998年 | 6篇 |
1997年 | 6篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 5篇 |
1993年 | 9篇 |
1992年 | 2篇 |
1991年 | 5篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 4篇 |
1978年 | 1篇 |
1976年 | 4篇 |
1969年 | 2篇 |
1967年 | 1篇 |
1966年 | 2篇 |
1959年 | 16篇 |
1958年 | 31篇 |
1957年 | 51篇 |
1956年 | 38篇 |
1955年 | 47篇 |
1954年 | 39篇 |
1953年 | 4篇 |
1952年 | 1篇 |
1951年 | 1篇 |
1950年 | 1篇 |
1949年 | 2篇 |
1948年 | 1篇 |
排序方式: 共有357条查询结果,搜索用时 0 毫秒
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
JACOB A. DOLL M.D. EUGENIA NIKOLSKY M.D. Ph .D. GREGG W. STONE M.D. ROXANA MEHRAN M.D. A. MICHAEL LINCOFF M.D. ADRIANO CAIXETA M.D. Ph .D. BRENT MCLAURIN M.D. ECATERINA CRISTEA M.D. MARTIN FAHY M.Sc . VIJAYA KESANAKURTHY M.D. ALEXANDRA J. LANSKY M.D. 《Journal of interventional cardiology》2009,22(5):453-459
Background: The lack of a specific counteragent to bivalirudin may complicate the management of patients with coronary artery (CA) perforation during percutaneous coronary intervention (PCI).
Aim: Assess outcomes of patients with CA perforation from three PCI trials comparing intravenous bivalirudin with provisional glycoprotein (GP) IIb/IIIa inhibition versus unfractionated heparin (UFH) plus GP IIb/IIIa.
Methods: A pooled analysis of patients treated with PCI in three randomized trials including REPLACE-2, ACUITY, and HORIZONS-AMI.
Results: Among a total of 12,921 patients, CA perforation occurred in 35 patients (0.27%). By multivariable analysis, baseline creatinine clearance was the only independent predictor of CA perforation (per 10 mL/min decrease, odds ratio [95% confidence interval]= 1.28 [1.11, 1.47], P = 0.0007). At 30 days, patients with versus without CA perforation had significantly (all P values ≤0.001) higher rates of 30-day mortality (11.4% vs. 1.0%), myocardial infarction (MI) [Q wave: 22.9% vs. 5.7%; non-Q wave: 17.1% vs. 4.9%], target vessel revascularization (TVR) [20.1% vs. 1.8%], and composite end-point of death/MI/TVR (31.4% vs. 7.8%). Patients assigned to bivalirudin versus UFH plus a GP IIb/IIIa inhibitor had nonsignificantly lower rates of death (0% vs. 18.8%, P = 0.08), similar rates of MI (26.7% vs. 25.0%, P = 0.92), significantly lower rates of TVR (6.7% vs. 37.5%, P = 0.04), and similar rates of the composite end-point of death/MI/TVR (35.5% vs. 26.7%, P = 0.54).
Conclusion: In three PCI trials, treatment of patients experiencing CA perforation with adjunctive antithrombotic therapy of bivalirudin monotherapy was not associated with worse outcomes compared to treatment with UFH plus GP IIb/IIIa inhibitors. 相似文献
Aim: Assess outcomes of patients with CA perforation from three PCI trials comparing intravenous bivalirudin with provisional glycoprotein (GP) IIb/IIIa inhibition versus unfractionated heparin (UFH) plus GP IIb/IIIa.
Methods: A pooled analysis of patients treated with PCI in three randomized trials including REPLACE-2, ACUITY, and HORIZONS-AMI.
Results: Among a total of 12,921 patients, CA perforation occurred in 35 patients (0.27%). By multivariable analysis, baseline creatinine clearance was the only independent predictor of CA perforation (per 10 mL/min decrease, odds ratio [95% confidence interval]= 1.28 [1.11, 1.47], P = 0.0007). At 30 days, patients with versus without CA perforation had significantly (all P values ≤0.001) higher rates of 30-day mortality (11.4% vs. 1.0%), myocardial infarction (MI) [Q wave: 22.9% vs. 5.7%; non-Q wave: 17.1% vs. 4.9%], target vessel revascularization (TVR) [20.1% vs. 1.8%], and composite end-point of death/MI/TVR (31.4% vs. 7.8%). Patients assigned to bivalirudin versus UFH plus a GP IIb/IIIa inhibitor had nonsignificantly lower rates of death (0% vs. 18.8%, P = 0.08), similar rates of MI (26.7% vs. 25.0%, P = 0.92), significantly lower rates of TVR (6.7% vs. 37.5%, P = 0.04), and similar rates of the composite end-point of death/MI/TVR (35.5% vs. 26.7%, P = 0.54).
Conclusion: In three PCI trials, treatment of patients experiencing CA perforation with adjunctive antithrombotic therapy of bivalirudin monotherapy was not associated with worse outcomes compared to treatment with UFH plus GP IIb/IIIa inhibitors. 相似文献